VivoSeq
Metabolic & Endocrine

Polycystic Ovary Syndrome

141

Pipeline Programs↗

23

Active Trials↗

36

Companies Involved↗

Polycystic Ovary Syndrome is a highly competitive landscape with 141 programs across 36 companies. The most active players are Amgen, Bayer, Pfizer. 45 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

25/100

Mech. Concentration

6/100

Completion Rate

88/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Phase 1Bayer logo

Bayer

4 programs

Phase 1Pfizer logo

Pfizer

2 programs

Phase 2S

Spruce Biosciences

1 program

Phase 2F

Fujian Shengdi Pharmaceutical Co., Ltd.

1 program

Phase 2K

Kunming Pharmaceuticals, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical42

Clomiphene Citrate

Ferring

Melatonin

Neurim Pharmaceuticals Ltd.

Clomiphene

EMD Serono

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Fenofibrate

Jagotec

Phase 18

Flutamide

Schering-Plough

Estradiol Valerate

Bayer

Estradiol

Novo Nordisk

Ganirelix Acetate

Yale University

Zoely

Mahidol University

Phase 224

Elagolix

AbbVie

Salsalate

Joslin Diabetes Center

Resveratrol

National Cancer Institute (NCI)

Atorvastatin Calcium

Merck & Co.

Exenatide

AstraZeneca

Phase 322

Metformin Hydrochloride

Boehringer Ingelheim

Dapagliflozin

AstraZeneca

Dexamethasone

Aspen Global Incorporated

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Recombinant Human Chorionic Gonadotropin

Merck & Co.

Approved45

Simvastatin

Organon and Co

Ganirelix

Organon and Co

Orlistat

Engelhard Arzneimittel GmbH & Co.KG

Raloxifene

Eli Lilly

Saxagliptin

AstraZeneca

Analysis

Modality Breakdown

97%

Small molecule

167 of 172 classified programs — the dominant modality here.

3%ALL OTHERSPeptide42%Cell therapy1<1%

Small molecule leads; the ring shows all 172 classified programs, each share of the total. Modality classified for 100% of 176 pipeline programs.

Analysis

Trial Status

189

clinical trials

Completed110 · 58%
Unknown status41 · 22%
Recruiting16 · 8%
Terminated12 · 6%
Not yet recruiting4 · 2%
Withdrawn2 · 1%
Other4 · 2%

Clinical Trials

Trial Activity

189 trials

Effect of ALA Combined With Letrozole on Polycystic Ovary Syndrome Clinical Outcome in Infertile Females
Recruiting·—·Phase 3·NCT06418347·150 enrolled
The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients
Recruiting·—·Phase 3·NCT06836128·102 enrolled
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Recruiting·—·Phase 1·NCT06045351·142 enrolled
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Recruiting·—·Phase 2/3·NCT06896981·30 enrolled
Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism
Recruiting·MMuhamed Ahmed Abdelmoaty Muhamed Alhagrasy·N/A·NCT06041204·200 enrolled
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
Recruiting·FFuture University in Egypt·Phase 3·NCT06576375·70 enrolled
The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with Polycystic Ovary Syndrome
Recruiting·IIsfahan University of Medical Sciences·Phase 1·NCT06642363·44 enrolled
Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome
Recruiting·SSichuan Provincial People's Hospital·Phase 1·NCT07106996·90 enrolled
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Recruiting·—·Phase 2·NCT07182526·150 enrolled
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Recruiting·UUniversity of Virginia·Phase 1·NCT03401047·37 enrolled
Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
Recruiting·PPeking University First Hospital·Phase 4·NCT05702905·75 enrolled
Dihydroartemisinin for the Treatment of Polycystic Ovary Syndrome
Recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06842524·150 enrolled
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Recruiting·UUniversity of Colorado, Denver·Phase 3·NCT05819853·80 enrolled
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
Recruiting·NNemours Children's Clinic·N/A·NCT07169136·20 enrolled
A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS)
Recruiting·FFundació Sant Joan de Déu·Phase 2·NCT05394142·364 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)